Status:

COMPLETED

Systemic Pharmacokinetics of BOL-303224-A

Lead Sponsor:

Bausch & Lomb Incorporated

Conditions:

Conjunctivitis, Bacterial

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This is a multi-center, open-label, single dose/multiple dose, pharmacokinetic study in participants with bacterial conjunctivitis. The purpose of this study is to determine the extent of systemic exp...

Eligibility Criteria

Inclusion

  • must be at least 18 years of age, any race
  • must have a clinical diagnosis of acute bacterial conjunctivitis and exhibit purulent conjunctival discharge and redness in both eyes
  • women of childbearing potential must utilize reliable contraceptive methods and have a negative pregnancy test

Exclusion

  • Pregnant or nursing women
  • known hypersensitivity to fluoroquinolones or to any of the ingredients in the study medication
  • use of any antibiotic within 72 hours of enrollment
  • participation in an ophthalmic drug or devise research study within 30 days prior to entry in this study

Key Trial Info

Start Date :

October 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2007

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT00407589

Start Date

October 1 2006

End Date

October 1 2007

Last Update

December 9 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cornerstone Eyecare

High Point, North Carolina, United States, 27262

Systemic Pharmacokinetics of BOL-303224-A | DecenTrialz